5 December 2025
EMADOC-1700519818-2668331
Committee for Veterinary Medicinal Products (CVMP)

Summary of opinion[1] (post-authorisation)

Dexdomitor

International non-proprietary name (INN): dexmedetomidine

On 4 December 2025, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion[2], recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Dexdomitor. The marketing authorisation holder for this veterinary medicinal product is Orion Corporation.

Dexdomitor is currently authorised as solution for injection for use in dogs and cats. The variation concerns change(s) to therapeutic indication(s) – addition of a new therapeutic indication or modification of an approved one for Dexdomitor 0.5 mg/ml solution for injection: to be administered intravenously as a constant rate infusion (CRI) in dogs and cats as part of a multimodal protocol during inhalation anaesthesia. Additionally, the product information has been aligned with version 9.1 of the QRD template.

Detailed conditions for the use of this product are described in the summary of product characteristics (SPC), for which an updated version reflecting the changes will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

[1] Summaries of opinion are published without prejudice to the Commission Decision.
[2] Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union